First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2

Notified -

Olon Group Strengthens Its Leadership in Bioproduction with Two Strategic Appointments in France

Notified -

Boehringer Ingelheim announces succession Chairmen Shareholders’ Committee and Board of Managing Directors

Notified -

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai

Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results

Olon Continues its Growth Path and Announces a New Acquisition

Olon Group Announces the Acquisition of GTP Bioways Group

Societal CDMO to Participate at 35th Annual Roth

SAN DIEGO and GAINESVILLE, Ga., March 03, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”;